Our team
MANAGEMENT TEAM

TORSTEN MUMMENBRAUER
Chief Executive Officer
TORSTEN MUMMENBRAUER
Torsten is CEO of ExeVir Bio. He brings nearly 25 years of experience in biotech and pharma to the role.
In prior roles, Torsten served as CEO of Velvio GmbH, Senior Vice President Business Development of Hookipa Pharma, Senior Director Business Development of Morphosys and Vice President Business Development of GSK, leading the transaction team of GSK vaccines. Torsten is reviewer of the German biotech seed fund program GoBio since almost 10 years and holds a PhD in Tumor Virology and Immunology from the University Hospital Hamburg.
Beyond his pharma and biotech engagement Torsten loves biking, skiing and windsurfing.

VIKI BOCKSTAL
Chief Scientific Officer
VIKI BOCKSTAL
Ever since the early beginning of her career, the focus of her interests has been on infectious diseases. Prior to joining ExeVir in 2021, Viki led various teams at J&J’s Janssen Infectious Diseases and Vaccines for nearly a decade. In her last role as Biomarker Lead for the Ebola and Filovirus programs, she was responsible for determining the immunological strategy to advance the Ebola vaccine regimen through accelerated clinical development from Phase 1 up to Marketing Authorization Approval by the European Commission. In previous roles, she also worked on the development of a new poliovirus vaccine and HIV vaccine. Viki is a Belgian American Educational Foundation (BAEF) alumnus.
In her free time, she enjoys spending time with her family and three young children, mountain biking, hiking and being outdoors.
SCIENTIFIC FOUNDERS

XAVIER SAELENS
XAVIER SAELENS
Professor Xavier Saelens, scientific founder of Exevir is a Group Leader at the VIB-UGent Center for Medical Biotechnology at VIB and a full Professor Molecular Virology at Ghent University.
His research is primarily focused on influenza and respiratory syncytial virus. The aim of this research is to develop new vaccines and antibody-based intervention strategies to prevent and treat disease caused by these and other important human respiratory viruses. A second line of research in the Saelens group aims to increase our knowledge on the molecular interactions between influenza and respiratory syncytial virus and their human host.

NICO CALLEWAERT
NICO CALLEWAERT
Professor Nico Callewaert, scientific founder of ExeVir, is Director at the VIB Center for Medical Biotechnology and Professor of Biochemistry and Biotechnology at Ghent University.
Based on strengths in glycobiology, microbial biotechnology, biological system’s engineering and bio-analytics, his research group is developing innovative molecular technology to enable novel approaches to the study, diagnosis and treatment of disease. Nico and his team have ample expertise in Protein production in mammalian cells, FEMTO Pulse Automated Pulsed-Field CE instrument, Sugar analysis – glycomics (DSA-FACE), Protein production in yeast, Recombinant DNA techniques for synthetic biology.